← Leaderboards
John E Tavis
Saint Louis University
$13,372,324
Attributed
$15,207,258
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,207,258 · 17
By mechanism
R01$12,272,070 · 7
U01$1,423,000 · 1
R21$1,074,151 · 3
R03$303,000 · 2
R29$111,037 · 1
R13$24,000 · 3
Top collaborators
- Marvin J Meyers7 shared
Most similar at Saint Louis University
Same institution · by research overlap
- Govindaswamy Chinnadurai$8,779,606
- Valerio Rasi$162,108
- Marvin J Meyers$5,628,117
- John A Corbett$16,763,280
- Ian Mitchelle Sayo De Vera$177,066
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralViral GenomeVirusGenomeAnalogChronicAffectReverse TranscriptionVirus ReplicationCellsViral RnaPharmaceutical PreparationsViral DnaDna VirusesRibonuclease HDna BiosynthesisHepatitis B VirusRecombinantsDna-Directed Dna PolymeraseVariantBiochemicalPreventCapsidLiver Failure
Grant awards (55)
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$661,369
R01 · FY2025 · AI · contact PI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$642,207
R01 · FY2024 · AI · contact PI
HBV RNaseH inhibitors: Effects on HBV biology and resistance development$378,750
R01 · FY2024 · AI · contact PI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$637,836
R01 · FY2023 · AI · contact PI
HBV RNaseH inhibitors: Effects on HBV biology and resistance development$378,750
R01 · FY2023 · AI · contact PI
2023 International HBV Meeting$7,000
R13 · FY2023 · AI · contact PI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$656,876
R01 · FY2022 · AI · contact PI
HBV RNaseH inhibitors: Effects on HBV biology and resistance development$378,750
R01 · FY2022 · AI · contact PI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$654,955
R01 · FY2021 · AI · contact PI
HBV RNaseH inhibitors: Effects on HBV biology and resistance development$378,750
R01 · FY2021 · AI · contact PI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH$440,118
R01 · FY2020 · AI · contact PI
HBV RNaseH inhibitors: Effects on HBV biology and resistance development$371,540
R01 · FY2020 · AI · contact PI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH$440,118
R01 · FY2019 · AI · contact PI
2019 International Meeting on the Molecular Biology of Hepatitis B Viruses$7,000
R13 · FY2019 · AI · contact PI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH$440,118
R01 · FY2018 · AI · contact PI
Defining approaches for improving HID and HPD compounds as HBV RNaseH antagonists$189,375
R21 · FY2018 · AI · contact PI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH$440,118
R01 · FY2017 · AI · contact PI
Defining approaches for improving HID and HPD compounds as HBV RNaseH antagonists$227,250
R21 · FY2017 · AI · contact PI
Structural studies of the HBV ribonuclease H$75,750
R03 · FY2017 · AI · contact PI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH$452,993
R01 · FY2016 · AI · contact PI
A screen for antiviral compounds targeting the Hepatitis B Virus ribonuclease H$337,500
R01 · FY2016 · AI · contact PI
Structural studies of the HBV ribonuclease H$75,750
R03 · FY2016 · AI · contact PI
A screen for antiviral compounds targeting the Hepatitis B Virus ribonuclease H$337,500
R01 · FY2015 · AI · contact PI
Hepatitis B Virus diversity and ribonuclease H inhibitor efficacy$75,750
R03 · FY2015 · AI · contact PI
A screen for antiviral compounds targeting the Hepatitis B Virus ribonuclease H$331,025
R01 · FY2014 · AI · contact PI
Hepatitis B Virus diversity and ribonuclease H inhibitor efficacy$75,750
R03 · FY2014 · AI · contact PI
HCV genetic variation and hepatocellular carcinoma$266,288
R01 · FY2012 · CA · contact PI
HCV genetic variation and hepatocellular carcinoma$266,288
R01 · FY2011 · CA · contact PI
Role of HCV Sequence Variation in Pathology$288,902
R01 · FY2010 · DK · contact PI
HCV genetic variation and hepatocellular carcinoma$274,523
R01 · FY2010 · CA · contact PI
Role of HCV Sequence Variation in Pathology$319,164
R01 · FY2009 · DK · contact PI
HCV genetic variation and hepatocellular carcinoma$274,523
R01 · FY2009 · CA · contact PI
Role of HCV Sequence Variation in Pathology$12,537
R01 · FY2009 · DK · contact PI
Role of HCV Sequence Variation in Pathology$318,528
R01 · FY2008 · DK · contact PI
HCV genetic variation and hepatocellular carcinoma$274,523
R01 · FY2008 · CA · contact PI
Variation in NTP use by the HCV polymerase and response to therapy$147,000
R21 · FY2008 · CA · contact PI
Variation in NTP use by the HCV polymerase and response to therapy$20,868
R21 · FY2008 · CA · contact PI
Role of HCV Sequence Variation in Pathology$13,452
R01 · FY2008 · DK · contact PI
Role of HCV Sequence Variation in Pathology$334,892
R01 · FY2007 · DK · contact PI
Variation in NTP use by the HCV polymerase and response to therapy$176,400
R21 · FY2007 · CA · contact PI
Variation in NTP use by the HCV polymerase and response to therapy$20,868
R21 · FY2007 · CA · contact PI
Analysis of the hepadnaviral reverse transcriptase$251,205
R01 · FY2006 · AI · contact PI
Analysis of the hepadnaviral reverse transcriptase$257,250
R01 · FY2005 · AI
Response of HCV to Therapy in African Americans$250,000
U01 · FY2005 · DK
Response of HCV to Therapy in African Americans$275,000
U01 · FY2004 · DK
Analysis of the hepadnaviral reverse transcriptase$257,250
R01 · FY2004 · AI
Response of HCV to Therapy in African Americans$275,000
U01 · FY2003 · DK
Analysis of the hepadnaviral reverse transcriptase$257,250
R01 · FY2003 · AI
International Conference on the Hepatitis B Viruses$10,000
R13 · FY2003 · AI
Response of HCV to Therapy in African Americans$475,000
U01 · FY2002 · DK
Analysis of the hepadnaviral reverse transcriptase$246,222
R01 · FY2002 · AI
Nonencapsidated HBV P protein as an anticancer target$148,000
R21 · FY2002 · CA
Response of HCV to Therapy in African Americans$148,000
U01 · FY2001 · DK
Nonencapsidated HBV P protein as an anticancer target$144,390
R21 · FY2001 · CA
HEPADNAVIRAL REVERSE TRANSCRIPTASE$111,037
R29 · FY2000 · AI